View in EDS HTML Full Text PDF Full Text

663. Efficacy and Safety of Lefamulin (LEF) vs. Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Clinical Trials

Saved in:

Bibliographic Details
Title:	663. Efficacy and Safety of Lefamulin (LEF) vs. Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Clinical Trials
Authors:	Shorr, Andrew F¹ (AUTHOR), Schranz, Jennifer² (AUTHOR), Goldberg, Lisa² (AUTHOR), Paukner, Susanne³ (AUTHOR), Das, Anita F⁴ (AUTHOR), Moran, Gregory J⁵ (AUTHOR), Sandrock, Christian⁶ (AUTHOR), File, Thomas M⁷ (AUTHOR), Alexander, Elizabeth² (AUTHOR), Gelone, Steven P² (AUTHOR)
Source:	Open Forum Infectious Diseases. 2019 Supplement, Vol. 6, pS303-S304. 2p.
Database:	Academic Search Ultimate
Full text is not displayed to guests. Login for full access.

Description
ISSN:	23288957
DOI:	10.1093/ofid/ofz360.731